Osmotica Pharmaceuticals Stock Forecast, Price & News

-0.04 (-1.14 %)
(As of 07/27/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume112,584 shs
Average Volume793,209 shs
Market Capitalization$217.80 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive OSMT News and Ratings via Email

Sign-up to receive the latest news and ratings for Osmotica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Osmotica Pharmaceuticals logo

About Osmotica Pharmaceuticals

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.36 out of 5 stars

Medical Sector

1033rd out of 2,218 stocks

Pharmaceutical Preparations Industry

501st out of 869 stocks

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Osmotica Pharmaceuticals (NASDAQ:OSMT) Frequently Asked Questions

Is Osmotica Pharmaceuticals a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Osmotica Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Osmotica Pharmaceuticals stock.
View analyst ratings for Osmotica Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Osmotica Pharmaceuticals?

Wall Street analysts have given Osmotica Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Osmotica Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals saw a decline in short interest in July. As of July 15th, there was short interest totaling 2,000,000 shares, a decline of 13.4% from the June 30th total of 2,310,000 shares. Based on an average daily trading volume, of 1,300,000 shares, the days-to-cover ratio is currently 1.5 days. Currently, 10.1% of the shares of the stock are sold short.
View Osmotica Pharmaceuticals' Short Interest

When is Osmotica Pharmaceuticals' next earnings date?

Osmotica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Osmotica Pharmaceuticals

How were Osmotica Pharmaceuticals' earnings last quarter?

Osmotica Pharmaceuticals plc (NASDAQ:OSMT) released its quarterly earnings data on Thursday, May, 13th. The company reported ($0.15) EPS for the quarter, topping the Zacks' consensus estimate of ($0.23) by $0.08. The company had revenue of $23.88 million for the quarter, compared to analysts' expectations of $32 million. Osmotica Pharmaceuticals had a negative trailing twelve-month return on equity of 38.01% and a negative net margin of 56.24%.
View Osmotica Pharmaceuticals' earnings history

How has Osmotica Pharmaceuticals' stock price been impacted by COVID-19?

Osmotica Pharmaceuticals' stock was trading at $5.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OSMT shares have decreased by 31.2% and is now trading at $3.48.
View which stocks have been most impacted by COVID-19

What price target have analysts set for OSMT?

2 Wall Street analysts have issued 12-month price objectives for Osmotica Pharmaceuticals' stock. Their forecasts range from $8.00 to $8.00. On average, they expect Osmotica Pharmaceuticals' share price to reach $8.00 in the next twelve months. This suggests a possible upside of 129.9% from the stock's current price.
View analysts' price targets for Osmotica Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Osmotica Pharmaceuticals' key executives?

Osmotica Pharmaceuticals' management team includes the following people:
  • Mr. Brian A. Markison, Chairman, Pres & CEO (Age 62, Pay $1.41M)
  • Mr. James D. Schaub, Exec. VP & COO (Age 39, Pay $668.3k)
  • Mr. Christopher A. Klein, Gen. Counsel & Sec. (Age 56, Pay $653.26k)
  • Dr. Tina Marie deVries, Exec. VP of R&D (Age 60, Pay $653.26k)
  • Mr. Andrew J. Einhorn, Chief Financial Officer (Age 61)
  • Mr. Jarret Miller, Exec. VP of HR

Who are some of Osmotica Pharmaceuticals' key competitors?

What other stocks do shareholders of Osmotica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Osmotica Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), AbbVie (ABBV), AT&T (T), (CGC), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), SCYNEXIS (SCYX), Zynerba Pharmaceuticals (ZYNE) and (AZN).

When did Osmotica Pharmaceuticals IPO?

(OSMT) raised $58 million in an initial public offering on Thursday, October 18th 2018. The company issued 8,300,000 shares at $7.00 per share. Jefferies, Barclays, RBC Capital MarketsWells and Fargo Securities served as the underwriters for the IPO.

What is Osmotica Pharmaceuticals' stock symbol?

Osmotica Pharmaceuticals trades on the NASDAQ under the ticker symbol "OSMT."

How do I buy shares of Osmotica Pharmaceuticals?

Shares of OSMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Osmotica Pharmaceuticals' stock price today?

One share of OSMT stock can currently be purchased for approximately $3.48.

How much money does Osmotica Pharmaceuticals make?

Osmotica Pharmaceuticals has a market capitalization of $217.80 million and generates $177.88 million in revenue each year. The company earns $-79,590,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

How many employees does Osmotica Pharmaceuticals have?

Osmotica Pharmaceuticals employs 302 workers across the globe.

What is Osmotica Pharmaceuticals' official website?

The official website for Osmotica Pharmaceuticals is

Where are Osmotica Pharmaceuticals' headquarters?

Osmotica Pharmaceuticals is headquartered at 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807.

How can I contact Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-809-1300 or via email at [email protected]

This page was last updated on 7/28/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.